Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$15.89
+2.2%
$0.00
$11.06
$63.00
$310.65M1.5277,644 shs171,070 shs
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
$3.15
-7.6%
$4.77
$1.04
$7.25
$47.13M-0.39873,973 shs120,657 shs
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$0.60
-0.2%
$0.57
$0.16
$0.82
$639.84M0.252.88 million shs1.51 million shs
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
$0.29
$0.37
$0.22
$4.79
$12.08M-0.281.09 million shs292,332 shs
Trevena, Inc. stock logo
TRVN
Trevena
$0.94
-14.5%
$1.12
$0.73
$7.85
$901K0.612,112 shs126 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
0.00%-0.06%-97.93%-97.93%-97.93%
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
0.00%+21.15%-41.67%-25.53%+105.88%
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.00%-15.78%+7.60%+87.33%+224.61%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
0.00%+10.09%-27.13%+8.43%-84.26%
Trevena, Inc. stock logo
TRVN
Trevena
0.00%-15.32%-10.65%-21.67%-81.93%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
3.3382 of 5 stars
3.80.00.03.72.51.70.6
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
0.5799 of 5 stars
0.03.00.00.02.11.70.0
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.5677 of 5 stars
0.03.00.00.02.90.80.0
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
1.4188 of 5 stars
3.02.00.00.00.60.01.3
Trevena, Inc. stock logo
TRVN
Trevena
1.6276 of 5 stars
3.04.00.00.00.60.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
3.67
Strong Buy$25.0057.33% Upside
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
0.00
N/AN/AN/A
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.00
N/AN/AN/A
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
2.00
Hold$3.381,071.88% Upside
Trevena, Inc. stock logo
TRVN
Trevena
2.00
Hold$5.00431.91% Upside

Current Analyst Ratings Breakdown

Latest CBIO, LPTX, TRVN, ELTP, and CPIX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$28.00
6/20/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/18/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$22.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$10K31,064.95N/AN/A$8.24 per share1.93
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
$37.87M1.24$0.26 per share12.25$1.61 per share1.96
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$84.04M7.61$0.02 per share34.91$0.05 per share11.98
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/AN/AN/AN/A$0.91 per shareN/A
Trevena, Inc. stock logo
TRVN
Trevena
$443K2.03N/AN/A($11.07) per share-0.08
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-$37.88M-$46.00N/AN/AN/AN/A-293.92%-206.20%N/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
-$6.48M-$0.25N/AN/A-7.98%6.92%2.33%8/5/2025 (Estimated)
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$20.11MN/A0.00N/A-25.70%-6.92%-3.94%8/14/2025 (Estimated)
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-$67.56M-$1.70N/AN/AN/AN/A-162.15%-120.05%8/11/2025 (Estimated)
Trevena, Inc. stock logo
TRVN
Trevena
-$40.29M-$47.04N/AN/AN/AN/AN/A-119.55%8/6/2025 (Estimated)

Latest CBIO, LPTX, TRVN, ELTP, and CPIX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/30/2025Q4 2025
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
N/A$0.01N/A$0.02N/A$32.00 million
5/13/2025Q1 2025
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-$0.38-$0.37+$0.01-$0.37N/AN/A
5/6/2025Q1 2025
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
N/A$0.15N/A$0.08N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
N/AN/AN/AN/AN/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
N/AN/AN/AN/AN/A
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
N/AN/AN/AN/AN/A
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/AN/AN/AN/AN/A
Trevena, Inc. stock logo
TRVN
Trevena
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
N/A
2.29
2.29
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
0.18
1.25
1.09
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.12
3.27
1.90
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/A
2.41
2.41
Trevena, Inc. stock logo
TRVN
Trevena
N/A
2.42
2.42

Institutional Ownership

CompanyInstitutional Ownership
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
75.19%
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
15.51%
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.01%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
30.46%
Trevena, Inc. stock logo
TRVN
Trevena
13.56%
CompanyEmployeesShares OutstandingFree FloatOptionable
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
2619.55 million18.77 millionNo Data
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
8014.96 million8.25 millionOptionable
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
401.07 billion914.31 millionNot Optionable
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
4041.44 million38.33 millionOptionable
Trevena, Inc. stock logo
TRVN
Trevena
40959,000841,000Optionable

Recent News About These Companies

Trevena, Inc. (TRVN) - Yahoo Finance
JMP Securities downgrades Trevena (TRVN) to a Hold
Lyme Regis town councillor John Trevena stand down
Trevena appoints new financial chief
Trevena Appoints Katrine Sutton as New CFO
HC Wainwright & Co. Downgrades Trevena (TRVN)
Why Trevena (TRVN) Stock Is Down 43% Today
Trevena, Inc. Faces Delisting from Nasdaq
Trevena Announces Receipt of Nasdaq Delisting Notification
Learn to Evaluate (TRVN) using the Charts

New MarketBeat Followers Over Time

Media Sentiment Over Time

Crescent Biopharma stock logo

Crescent Biopharma NASDAQ:CBIO

$15.89 +0.34 (+2.19%)
As of 07/3/2025 12:59 PM Eastern

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Cumberland Pharmaceuticals stock logo

Cumberland Pharmaceuticals NASDAQ:CPIX

$3.15 -0.26 (-7.62%)
As of 07/3/2025 03:23 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Elite Pharmaceuticals stock logo

Elite Pharmaceuticals OTCMKTS:ELTP

$0.60 0.00 (-0.15%)
As of 07/3/2025 12:59 PM Eastern

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. Elite Pharmaceuticals, Inc. was incorporated in 1997 and is headquartered in Northvale, New Jersey.

Leap Therapeutics stock logo

Leap Therapeutics NASDAQ:LPTX

$0.29 0.00 (0.00%)
Closing price 07/3/2025 03:13 PM Eastern
Extended Trading
$0.29 0.00 (0.00%)
As of 07/3/2025 04:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Trevena stock logo

Trevena NASDAQ:TRVN

$0.94 -0.16 (-14.55%)
As of 07/3/2025 12:34 PM Eastern

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.